soul trial oral semaglutide cardiovascular outcomes results 2024 2025 nejm Reduces CV Events in T2DM – (NEJM, Mar 2025) Relevant for: cardiology, diabetology, nephrology, internal medicine 🧪 T2DM + ASCVD/CKD 💊 Oral semaglutide 14 mg vs placebo 📉 STRIDE and SOUL: Semaglutide Improves

Importantly, the CD20 cell surface marker is found on most malignant B cells

Phase 1 trials are the trials to collect safety data in humans

While it's unlikely that Novo will suffer from a Nokia-style collapse soon, some obstacles are on the horizon that could hamper its growth in the future

aleniglipron does not T2D data : Orforglipron has ACHIEVE-3 head-to-head vs oral semaglutide Company backing : Eli Lilly (orforglipron) vs Structure Therapeutics (aleniglipron) Conclusion# The oral GLP-1 small molecule space is developing into a two-horse race between aleniglipron and orforglipron

The 24% figure from retatrutide Phase 2, over a shorter timeframe, is meaningfully ahead of both

Step 6: Maintain consistency